Belgian immunotherapy firm eTheRNA has received a €6.9 million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat cancers.
Merck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a few weeks, making GlaxoSmithKline’s $4.2 billion licensing deal for the drug lo
Rubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel cell therapies targeting cancer and autoimmune diseases.
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filin
The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung cancers and thyroid cancers, which the company said could herald a new er
Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.